- Home
- WFRD vs PTCT Comparison
WFRD vs PTCT Comparison
Compare WFRD & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WFRD
- PTCT
- Stock Information
- Founded
- WFRD 1941
- PTCT 1998
- Country
- WFRD United States
- PTCT United States
- Employees
- WFRD N/A
- PTCT N/A
- Industry
- WFRD Metal Fabrications
- PTCT Biotechnology: Pharmaceutical Preparations
- Sector
- WFRD Industrials
- PTCT Health Care
- Exchange
- WFRD Nasdaq
- PTCT Nasdaq
- Market Cap
- WFRD 4.1B
- PTCT 5.3B
- IPO Year
- WFRD N/A
- PTCT 2013
- Fundamental
- Price
- WFRD $72.30
- PTCT $75.70
- Analyst Decision
- WFRD Strong Buy
- PTCT Buy
- Analyst Count
- WFRD 8
- PTCT 17
- Target Price
- WFRD $86.13
- PTCT $73.24
- AVG Volume (30 Days)
- WFRD 974.0K
- PTCT 1.1M
- Earning Date
- WFRD 10-21-2025
- PTCT 11-04-2025
- Dividend Yield
- WFRD 1.39%
- PTCT N/A
- EPS Growth
- WFRD N/A
- PTCT N/A
- EPS
- WFRD 5.52
- PTCT 8.94
- Revenue
- WFRD $4,970,000,000.00
- PTCT $1,779,150,000.00
- Revenue This Year
- WFRD N/A
- PTCT $119.02
- Revenue Next Year
- WFRD N/A
- PTCT N/A
- P/E Ratio
- WFRD $13.07
- PTCT $8.42
- Revenue Growth
- WFRD N/A
- PTCT 97.54
- 52 Week Low
- WFRD $36.74
- PTCT $35.95
- 52 Week High
- WFRD $87.63
- PTCT $76.80
- Technical
- Relative Strength Index (RSI)
- WFRD 55.45
- PTCT 79.67
- Support Level
- WFRD $68.86
- PTCT $69.23
- Resistance Level
- WFRD $76.94
- PTCT $73.98
- Average True Range (ATR)
- WFRD 2.87
- PTCT 2.67
- MACD
- WFRD -0.26
- PTCT 0.40
- Stochastic Oscillator
- WFRD 42.82
- PTCT 89.08
About WFRD Weatherford International plc
Weatherford International provides diversified oilfield services across international markets for an array of oilfield types. The firm is a global market leader in artificial lift and tubular running services. Other key product lines include cementing products, directional drilling, and wireline evaluation.
About PTCT PTC Therapeutics Inc.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.